Novartis
NEWS
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
With regulatory approvals beginning to break through, attendees at ISCT’s annual meeting set out along the translational pathway. Organizers shared their findings with BioSpace.
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
Novartis announced on Thursday that it will be temporarily and voluntarily suspending the production of its cancer therapeutics Lutathera and Pluvicto at facilities in Italy and New Jersey.
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
BeiGene’s candidate drug tislelizumab for cancer succeeded in meeting the primary endpoint of overall survival in a global Phase III trial. Learn more about it here.
JOBS
IN THE PRESS